Printer Friendly

Company to develop iPSC-derived cell therapies for diabetes, spinal cord injury.

SAN DIEGO, Calif., January 6, 2017 -- Privately-held Allele Biotechnology & Pharmaceuticals will develop induced pluripotent stem cell (iPSC)-derived cell therapies after its plan was approved by the scientific advisory board and board of directors.

"We will apply innovative stem cell technologies to find new ways of treating disease, particularly to help people with difficult-to-treat conditions."

Allele has developed proprietary techniques to generate iPSCs and to derive high quality tissue specific cells with much less technical difficulties than other known methods.

In 2016, Allele established specialized cell culture clean rooms which will be dedicated to expanding donor cells, creating iPSC lines, and differentiating iPSCs into various tissue cells using Allele's own protocols in compliance with current good manufacturing and tissue practices.

As its first priority, Allele will begin iPSC-derived cell therapy programs to treat diabetes and spinal cord injury.

In the meantime, researchers at Allele will prepare additional therapeutic applications and explore new regulatory pathways suitable for future personalized cell therapies.


COPYRIGHT 2017 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:New Product Development
Publication:Stem Cell Business News
Date:Jan 9, 2017
Previous Article:Company files patent on AmnioStem stroke therapy.
Next Article:Neuralstem announces 1-for-13 reverse stock split.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters